According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. 

“This study represents a major step forward in how we respond to cardiac arrest in the United States,” explained Monique Starks, MD, principal investigator. “By integrating drone technology into emergency care, we’re working to close the critical gap between cardiac arrest and treatment."

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

"These provisions are contained in what amounts, in many cases, to contracts of adhesion, because a physician’s only choice is to accept the terms of the contract without revision or else forgo employment," the Society for Cardiovascular Angiography and Interventions wrote to the U.S. Federal Trade Commission.

One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.

With no treatments available that directly improve INOCA, this breakthrough device offers hope.

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Boston Scientific said two category III CPT codes are set to become permanent category I codes for physician payments starting Jan. 1, 2027. 

Masimo’s complaint over the new version of the Apple Watch could lead to an import ban if it is found that the technology infringes on its patents.